Guardant Health Inc (GH)
16.07
-0.62
(-3.71%)
USD |
NASDAQ |
Apr 19, 16:00
16.07
0.00 (0.00%)
After-Hours: 20:00
Guardant Health Cash from Financing (TTM): 477.38M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 477.38M |
September 30, 2023 | 389.12M |
June 30, 2023 | 366.01M |
March 31, 2023 | -189.94M |
December 31, 2022 | -189.09M |
September 30, 2022 | -187.63M |
June 30, 2022 | -173.88M |
March 31, 2022 | 3.117M |
December 31, 2021 | -66.82M |
September 30, 2021 | 976.12M |
June 30, 2021 | 982.48M |
Date | Value |
---|---|
March 31, 2021 | 1.339B |
December 31, 2020 | 1.410B |
September 30, 2020 | 366.66M |
June 30, 2020 | 372.73M |
March 31, 2020 | 366.48M |
December 31, 2019 | 367.30M |
September 30, 2019 | 614.59M |
June 30, 2019 | 608.52M |
March 31, 2019 | 294.18M |
December 31, 2018 | 293.16M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-189.94M
Minimum
Mar 2023
1.410B
Maximum
Dec 2020
412.23M
Average
367.30M
Median
Dec 2019
Cash from Financing (TTM) Benchmarks
Exact Sciences Corp | 159.77M |
Illumina Inc | -1.21B |
Delcath Systems Inc | 51.78M |
CytoSorbents Corp | 14.47M |
Progyny Inc | -11.07M |